Treatment options for metastatic melanoma have advanced dramatically in the last ten years, with BRAF inhibitors (e.g., Vemurafenib and Dabrafenib), in mono-therapy or combination-therapy schemes, ameliorating patient survival and improving progression-free disease [17,18,19,20,21]. This evidence concerns the gene BRAF and metastatic melanoma.